Showing 7811-7820 of 8181 results for "".
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- "Parasols of Protection" Highlights UV Safetyhttps://practicaldermatology.com/news/20130624-parasols_of_protection_highlights_uv_safety/2459512/Kicking off the summer with an educational sun protection campaign, the Women's Dermatologic Society (WDS), Duane Reade, and La Roche-Posay's Parasols of Protection event raised awareness about skin cancer through a
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with moder
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for